NAD+review2021

Engineering natural and noncanonical nicotinamide cofactor-dependent enzymes: design principles and technology development.

Current opinion in biotechnology

confidence

Key findings

Review of design principles and technologies for engineering natural and noncanonical nicotinamide cofactor-dependent enzymes; no clinical or biological endpoints reported.

View source on PubMed (PMID 32956903) ↗

Sample size
N/A
Population
Not applicable (review article on enzyme engineering)
Dosing
N/A
Duration
N/A
Route
N/A
Blinding
not_reported
Controls
not_reported
Drug class
coenzyme
Full abstract

Nicotinamide cofactors enable oxidoreductases to catalyze a myriad of important reactions in biomanufacturing. Decades of research has focused on optimizing enzymes which utilize natural nicotinamide cofactors, namely nicotinamide adenine dinucleotide (phosphate) (NAD(P)+). Recent findings reignite the interest in engineering enzymes to utilize noncanonical cofactors, the mimetics of NAD+ (mNADs), which exhibit superior industrial properties in vitro and enable specific electron delivery in vivo. We compare recent advances in engineering natural versus noncanonical cofactor-utilizing enzymes, discuss design principles discovered, and survey emerging high-throughput platforms beyond the traditional 96-well plate-based methods. Obtaining mNAD-dependent enzymes remains challenging with a limited toolkit. To this end, we highlight design principles and technologies which can potentially be translated from engineering natural to noncanonical cofactor-dependent enzymes.

Research information, not medical advice. StudyKit summarizes published studies to help you understand your protocol. It does not diagnose, treat, or replace a clinician. Talk to a qualified provider before changing anything you take.